

1 **Maternal SARS-CoV-2 impacts fetal placental macrophage programs and**
2 **placenta-derived microglial models of neurodevelopment**

3
4 Lydia L. Shook*^{1,2}, Rebecca A. Batorsky*³, Rose M. De Guzman^{1,2,4}, Liam T. McCrea^{4,5},
5 Sara M. Brigida¹, Joy E. Horng^{4,5}, Steven D. Sheridan^{4,5}, Olha Kholod⁷, Aidan M. Cook⁸,
6 Jonathan Z. Li⁶, Brittany A. Goods*^{7,8}, Roy H. Perlis*^{4,5}, Andrea G. Edlow MD*^{1,2+}

7
8 *Equal Contributions

9
10 **Affiliations:**

11 ¹Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston,
12 MA, USA

13 ²Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical
14 School, Boston, MA, USA

15 ³Data Intensive Studies Center, Tufts University, Boston, MA, USA

16 ⁴Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA

17 ⁵Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School,
18 Boston, MA, USA

19 ⁶Department of Medicine, Brigham and Women's Hospital, Harvard Medical School,
20 Boston, MA, USA

21 ⁷Thayer School of Engineering and Program, Dartmouth College, Hanover, NH, USA

22 ⁸Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth
23 College, Lebanon, NH, USA

24
25 **+Corresponding Author:**

26 Andrea G. Edlow, MD, MSc

27 Vincent Center for Reproductive Biology

28 Massachusetts General Hospital

29 55 Fruit Street, Thier Research Building, 903B, Boston, MA 02114

30 Ph: 617-724-0654

31 Email: aedlow@mg.harvard.edu

32
33 **Disclosure Statement:** R.H.P. has received fees for service as a scientific advisor to
34 Belle Artificial Intelligence, Burrage Capital, Circular Genomics, Genomind, Swan
35 Artificial Intelligence Studios, and Vault Health. A.G.E. serves as a consultant for Mirvie,
36 Inc. and receives research funding from Merck Pharmaceuticals outside of this work.
37 The other authors have no disclosures to report.

38 **ABSTRACT**

39 The SARS-CoV-2 virus activates maternal and placental immune responses,
40 which in the setting of other infections occurring during pregnancy are known to impact
41 fetal brain development. The effects of maternal immune activation on
42 neurodevelopment are mediated at least in part by fetal brain microglia. However,
43 microglia are inaccessible for direct analysis, and there are no validated non-invasive
44 surrogate models to evaluate *in utero* microglial priming and function. We have
45 previously demonstrated shared transcriptional programs between microglia and
46 Hofbauer cells (HBCs, or fetal placental macrophages) in mouse models. Here, we
47 assessed the impact of maternal SARS-CoV-2 on HBCs isolated from term placentas
48 using single-cell RNA-sequencing. We demonstrated that HBC subpopulations exhibit
49 distinct cellular programs, with specific subpopulations differentially impacted by SARS-
50 CoV-2. Assessment of differentially expressed genes implied impaired phagocytosis, a
51 key function of both HBCs and microglia, in some subclusters. Leveraging previously
52 validated models of microglial synaptic pruning, we showed that HBCs isolated from
53 placentas of SARS-CoV-2 positive pregnancies can be transdifferentiated into
54 microglia-like cells, with altered morphology and impaired synaptic pruning behavior
55 compared to HBC models from negative controls. These findings suggest that HBCs
56 isolated at birth can be used to create personalized cellular models of offspring
57 microglial programming.

58

59 **Keywords:** Hofbauer cells; microglia; single-cell RNA sequencing; fetal brain; placenta;
60 neurodevelopment; neuroimmune; SARS-CoV-2, COVID-19

61 INTRODUCTION

62 Multiple population-based studies have suggested that maternal infection during
63 pregnancy may have a transgenerational impact on offspring neurodevelopment. Initial
64 work found that the incidence of schizophrenia was increased after influenza pandemics
65 in Finland (1), Denmark (2), and the UK (3). Subsequent registry studies directly
66 examining the association of maternal infection requiring hospitalization during
67 pregnancy with diagnoses of autism and other neurodevelopmental disorders in
68 offspring also found risk to be increased (4, 5). Using electronic health records, we
69 identified an increased risk of delayed acquisition of speech and motor milestones,
70 beyond that attributable to prematurity, in a US cohort of offspring whose mothers had
71 SARS-CoV-2 during pregnancy. (6, 7). Similarly, authors of a prospective cohort study
72 of 127 children in Brazil found an increased risk of neurodevelopmental delay with *in*
73 *utero* SARS-CoV-2 exposure during pregnancy (8), and a recent meta-analysis of
74 smaller studies identified additional evidence of neurodevelopmental sequelae –
75 including reductions in fine motor and problem-solving skills – in infants with *in utero*
76 SARS-CoV-2 exposure compared to unexposed and pre-pandemic cohorts (9). If these
77 early signals foreshadow an increased risk of neurodevelopmental disorders in
78 childhood and adulthood, the public health implications could be profound, given the
79 significant number of pregnancies exposed to SARS-CoV-2 infection.

80 Despite the convergence of studies suggesting that maternal viral infection may
81 increase offspring risk for neurodevelopmental disorders, the precise biological
82 mechanisms leading to offspring neurodevelopmental vulnerability are not known.
83 Direct placental and fetal infection with SARS-CoV-2 virus is uncommon based on

84 current evidence (10–13), and thus vertical transmission is unlikely to be a major cause
85 of neurodevelopmental sequelae. Animal models of maternal immune activation (MIA),
86 in which offspring of pregnant dams treated with an immune stimulus recapitulate the
87 behavioral hallmarks of human neurodevelopmental disorders, have been used for
88 decades to investigate candidate *in utero* mechanisms of neurodevelopmental
89 programming (14–17). Embryonic microglia have emerged as central mediators of
90 offspring neuropathology in the setting of MIA (14). However, microglia from surviving
91 offspring are inaccessible for direct analysis in humans, necessitating alternative
92 models for evaluating the impact of SARS-CoV-2 on the fetal brain.

93 Prior work from our group has identified remarkable similarities in the
94 transcriptional programs and reactivity of fetal placental macrophages, or Hofbauer cells
95 (HBCs), and fetal brain microglia isolated from mouse embryos (18, 19). These two cell
96 types share an embryonic origin in the fetal yolk sac (20, 21), and both carry the imprint
97 of the *in utero* environment, with fetal yolk sac-derived macrophages serving as the
98 progenitors for the lifelong pool of microglia (22, 23). Here, we investigate the impact of
99 SARS-CoV-2 exposure on the transcriptional profiles of HBC subpopulations to gain
100 insight into fetal resident tissue macrophage programming. Our results demonstrate
101 that HBCs are a heterogeneous cell type, with eight subpopulations exhibiting distinct
102 cellular programs, and that maternal SARS-CoV-2 infection is associated with varying
103 impact on function in these subpopulations. Assessment of differentially expressed
104 genes implies impaired phagocytosis in specific subclusters, a key function of both
105 HBCs and microglia; we confirm these effects using a previously validated assay of
106 microglial synaptic pruning via synaptosome phagocytosis. In aggregate, we

107 demonstrate the application of HBC-based cellular models to gain non-invasive insight
108 into the impact of *in utero* exposures on fetal brain development.

109

110 **RESULTS**

111 ***Hofbauer cells are a heterogeneous population with subclusters demonstrating*** 112 ***both M1- and M2-like transcriptional signatures***

113 Placental chorionic villous tissues were collected from N=12 birthing individuals:
114 N=4 from individuals who had a positive SARS-CoV-2 nasopharyngeal PCR test during
115 pregnancy, and N=8 from birthing individuals with a negative PCR at delivery and no
116 history of a positive SARS-CoV-2 test during pregnancy. In SARS-CoV-2 positive
117 maternal cases, infections occurred remote from delivery (median 19.5 weeks). No
118 participants had received a COVID-19 vaccine prior to or during pregnancy and no
119 placental samples were infected with SARS-CoV-2 at delivery (defined as having
120 detectable SARS-CoV-2 viral load in a validated assay sensitive to 40 copies/mL) (24,
121 25). Thus, SARS-CoV-2 positive cases were defined by maternal infection in
122 pregnancy, not placental or fetal infection. Additional participant characteristics are
123 provided in Table 1.

124 To assess the HBC transcriptome, we first used a previously-described protocol
125 to obtain primarily HBCs from placental villi; in this protocol, a Percoll-based gradient
126 and negative bead-based selection steps are used to isolate putative HBCs from other
127 cell types present in the chorionic villi (including trophoblasts, fibroblasts) (26). Single-
128 cell RNA sequencing was then performed on all cell suspensions (10x Genomics). After

129 quality control filtering to remove putative doublets and cells with less than 300
130 identified genes, we obtained a dataset comprised of a total of 70,817 cells. We then
131 performed sample integration and graph-based clustering to identify broad cell types
132 (Figure S1A). Based on analyses of marker gene expression (Figure S1B), we found
133 that the majority of cells in our dataset had marker gene expression consistent with
134 monocytes/macrophages, and that other cell types were represented to a lesser extent,
135 including some fibroblasts, vascular endothelial cells (VECs), extravillous trophoblasts
136 (EVTs), leukocytes (NK cells, CD8+ T cells, B cells), neutrophils and red blood cells
137 (Figure S1C). From this dataset, we excluded all cell types that were not identifiable as
138 macrophages/monocytes. After additional quality control filtering for nUMIs, gene
139 counts, and percent mitochondrial reads (see Methods), this resulted in a dataset
140 containing 31,719 high-quality placental macrophages/monocytes. All subsequent
141 analyses were performed with this final dataset.

142 After re-processing selected cells for quality control as described, we identified
143 10 total subclusters of macrophages/monocytes (Figure 1A), with representation of
144 each subcluster across donors from both SARS-CoV-2 positive cases and controls
145 (Figure S2A). To distinguish HBCs, which are placental macrophages of fetal origin,
146 from macrophages or monocytes of maternal origin, we used cells isolated from male
147 placentas (N=10). Male fetal origin was confirmed by high expression of *DDX3Y* and
148 low expression of *XIST* in 8 subclusters; these were labeled HBC 0-7 (Figure 1B). The
149 macrophage cluster with high expression of *XIST* (consistent with maternal origin) was
150 annotated as placenta-associated maternal macrophages and monocytes (PAMMs,
151 Figure 1B) (27). A small cluster of monocytes – identified as such by high expression of

152 monocyte marker genes *S100A8*, *S100A9*, and *TIMP1* – demonstrated equal
153 expression levels of both *DDX3Y* and *XIST*, suggesting that both fetal and maternal
154 cells were present in this monocyte cluster. To further support HBC cluster annotation,
155 we next compared the overall gene expression profiles of each cluster to a previously
156 published single-cell dataset derived from human first-trimester placenta and decidua
157 (28). In this analysis, all putative HBC subclusters showed highest correlation with HBC
158 expression profiles from this dataset, whereas the monocyte and PAMM clusters had
159 higher correlation with decidual macrophages than HBCs (Figure 1C).

160 To delineate differences in the identity and functions of HBC subclusters, we next
161 assessed top marker genes defining each subcluster, shown as an average heatmap
162 (Figure 1D). Marker genes for HBC clusters 3, 4, 5, and 7 suggested involvement in
163 classic M1 macrophage/pro-inflammatory activities. HBC cluster 3 demonstrated high
164 expression of chemokine (C-X-C motif) ligand genes (*CXCLs*) as well as pro-
165 inflammatory marker genes *IL1B*, *IL1A*, *TNF*, and *NFKB1*. HBC cluster 4 demonstrated
166 high expression of multiple CC chemokine ligand genes (*CCLs*) in a profile similar to
167 that observed in HBCs responding to lipopolysaccharide stimulation *in vitro* (29). HBC
168 cluster 5 was characterized by high expression of genes encoding major
169 histocompatibility complex (MHC) class II molecules (human leukocyte antigen (HLA)-
170 *DRA/B1* and *-DP*) and Fc-gamma binding protein (*FCGBP*), suggesting a role in antigen
171 presentation to CD4⁺ T cells. MHC class II molecules are critical to antigen-specific
172 responses, and upregulation of HLA complexes and antigen presentation pathways has
173 been observed in proteomic analyses of HBCs stimulated with the viral dsRNA mimic
174 poly(I:C) (29). HBC cluster 7 demonstrated marker genes from the interferon-induced

175 protein with tetratricopeptide repeats (*IFIT*) family (*IFIT2*, *IFIT3*), *CXCL10*, *ISG15*, and
176 *MX1*, associated with a pro-inflammatory type 1 interferon antiviral response. To gain
177 further insight into the biological processes reflected in each HBC subcluster, we
178 performed Gene Ontology (GO) enrichment analyses of cluster marker genes (Figure
179 1E). As would be expected given marker gene expression noted previously, pathways
180 involved in M1-like immune/inflammatory responses were enriched in HBC 3, 4, 5, and
181 7, including “response to interleukin-1,” “response to interferon-gamma,” “response to
182 tumor necrosis factor,” and “positive regulation of cytokine production.”

183 Gene signatures of HBC clusters 0, 1, and 2 reflected engagement in specific
184 stress response processes, particularly response to inflammation and/or tissue damage,
185 to ultimately support placental function. HBC 0 and HBC 1 were characterized by genes
186 encoding heat shock proteins and other proteins involved in endoplasmic reticulum
187 stress and the unfolded protein response, such as *HSPA6*, *HSPA1B*, *DNAJB1*,
188 *HSP90B1*, *HSPA5* and *BAG3*. The unfolded protein response represents a homeostatic
189 response to restore balance when endoplasmic reticulum stress is sensed and to
190 modulate and/or resolve inflammation (30). Additionally, HBC 0’s high expression of
191 *PDK4* and *KLF2* may suggest involvement in attenuating oxidative stress responses
192 and reducing pro-inflammatory cytokine production (31, 32), and HBC 1’s high
193 expression of *FABP5* and *HMOX1* suggests engagement in anti-inflammatory
194 responses against heme-induced toxicity and induction towards M2 polarization (33,
195 34). GO enrichment analysis of these clusters similarly demonstrated enrichment of
196 pathways such as “response to unfolded protein”, “response to heat”, “response to
197 endoplasmic reticulum stress”, and pathways related to cellular stress response and

198 apoptosis (e.g. “extrinsic apoptotic signaling pathway”, “response to oxidative stress”
199 and “ERK1 and ERK2 cascade”).

200 GO enrichment analysis also suggested both HBC 0 and HBC 1 were engaged in
201 homeostatic functions including “receptor-mediated endocytosis”, “regulation of
202 angiogenesis” and “vascular development”, and nutrient-sensing functions such as
203 “response to nutrient levels” and “response to starvation.” HBC 2 was characterized by
204 high expression of the genes encoding secreted phosphoprotein 1 (*SPP1*) and
205 Nicotinamide N -methyltransferase (*NNMT*), both associated with M2 (anti-
206 inflammatory) macrophage polarization in the context of tumor-associated macrophages
207 (35, 36); *SPP1*, also known as osteopontin, is secreted by HBCs and plays an important
208 role in endothelial biology and angiogenesis (37). GO analysis of HBC cluster 2 also
209 demonstrated enrichment in “receptor-mediated endocytosis” (involved in intracellular
210 transport of macromolecules), as well as “cellular lipid catabolic process,” and
211 processes associated with stromal tissue development.

212 HBC 6 was characterized by expression of genes involved in regulation of actin
213 polymerization and cytoskeleton organization (*TMSB4X* and *AIF1*, which encodes the
214 canonical microglial marker *Iba1* (38)) and several ribosomal proteins including *RPS18*,
215 *RPS23*, and *RPS4Y1*. GO enrichment analysis of this cluster demonstrates highly
216 specific enrichment of protein processing pathways (e.g. “protein targeting” pathways,
217 “cytoplasmic translation,” “translational initiation”) and pathways related to RNA
218 catabolism, oxidative phosphorylation, and ATP metabolism. Marker genes of the
219 maternal PAMM subcluster included *APOE*, *APOC1*, *VIM*, *LGALS1*, and *GPNMB*
220 among others, an expression pattern consistent with previously reported maternal

221 placental macrophage transcriptional profiles (39, 40). High expression of *LGALS1/3*
222 and *GPNMB* by the PAMM cluster suggests a role in inflammation regulation (41–43),
223 which was echoed by GO analyses identifying enrichment in immune response and
224 immunomodulatory pathways (e.g. “antigen processing and presentation, “positive
225 regulation of cytokine production”, and “regulation of innate immune response”) . In
226 addition, GO enrichment analysis demonstrated PAMM were engaged in lipid metabolic
227 processes and receptor-mediated endocytosis, consistent with their known involvement
228 in lipid engulfment, and tissue repair/scar formation (37, 39).

229

230 ***Maternal SARS-CoV-2 infection drives cluster-specific differences in immune***
231 ***signaling and metabolic pathways***

232 Once the baseline functions of HBC and PAMM subclusters had been
233 established, we then sought to characterize the impact of maternal SARS-CoV-2
234 infection on the transcriptomic profile of HBC subclusters. To do so, we identified
235 differentially expressed genes (DEG) by maternal SARS-CoV-2 status within each
236 cluster. DEG were defined using log fold-change threshold of 0.2 and adjusted p-value
237 of 0.05 (see Methods for full details). We first verified that each subcluster included
238 representation from both SARS-CoV-2+ cases and controls (Figure 2A, top panel). The
239 proportion of cells from cases versus controls was consistent across all subclusters,
240 except for HBC 0, which demonstrated a relatively high contribution of control donor
241 cells (Figure S2A). Of the 8 HBC clusters, a majority (5) were significantly impacted by
242 maternal SARS-CoV-2 infection: HBC 0, 1, 2, 3, and 5 (Figure 2A, bottom panel). In
243 contrast, HBC clusters 4, 6, and 7 had very few DEG in the setting of maternal SARS-

244 CoV-2 exposure, with three, zero, and two DEG respectively. Of the 5 highly impacted
245 clusters, HBC 1 and HBC 5 had the highest number of DEG by maternal SARS-CoV-2,
246 with 723 and 566 DEG, respectively. PAMMs were impacted by SARS-CoV-2 to a
247 lesser extent, with 67 DEG identified. Both up- and down-regulated DEG were
248 identified across all impacted clusters.

249 GO pathway enrichment analysis of DEG indicated that in the context of maternal
250 SARS-CoV-2 infection, specific pathways involved in immune responses were enriched
251 in all impacted HBC clusters (HBC 0, 1, 2, 3 and 5), including response to
252 lipopolysaccharide, response to interferon-gamma, cellular response to tumor necrosis
253 factor, and regulation of T cell activation (Figure 2B). Additionally, all subclusters were
254 enriched for pathways related to cellular movement, such as cell chemotaxis, leukocyte
255 cell-cell adhesion, and myeloid leukocyte migration; heat shock-related pathways
256 (unfolded protein response); and phagocytosis pathways.

257 GO enrichment analysis also indicated some biological processes that were only
258 dysregulated in specific clusters in the setting of maternal SARS-CoV-2 infection (Figure
259 2B). For example, regulation of vascular development was only dysregulated in HBC 0
260 and the PAMM cluster, regulation of lipid metabolism and transport were dysregulated
261 in all clusters except HBC 5, more cellular energy utilization pathways (e.g. ATP
262 metabolism, electron transport chain/oxidative phosphorylation and cellular respiration)
263 and cellular stress/apoptosis pathways were impacted in HBC clusters relative to the
264 PAMM cluster, and protein processing and actin cytoskeleton organization pathways
265 were only dysregulated in HBC clusters but not PAMMs. Taken together, these
266 functional analyses suggest that in the context of maternal SARS-CoV-2 infection, HBC

267 subclusters and PAMMs are differentially impacted, with key dysregulated biological
268 processes including innate immune and pro-inflammatory signaling, cell chemotaxis and
269 migration, cellular ATP and lipid metabolism, cellular phagocytosis, and the unfolded
270 protein response.

271 To better understand the impact of SARS-CoV-2 on HBC functions, we next used
272 Ingenuity Pathway Analysis (IPA), which predicts strength and directionality (i.e.
273 activation or suppression) of enriched canonical pathways by subcluster. In this
274 analysis, pathways with absolute Z-score value greater than 1 (consistent with IPA
275 being able to “call” a direction of dysregulation of the pathway) and Benjamini
276 Hochburg-adjusted $p < 0.05$ were included and displayed by subcluster (Figure 2C and
277 Figure S2B-F). Z-scores ≥ 1 indicate upregulated signaling in the pathway and ≤ 1
278 indicate downregulated pathway signaling (44). Both HBC 1 and HBC 2 subclusters
279 exhibited a primarily anti-inflammatory response to SARS-CoV-2, with activation of
280 PPAR signaling and oxidative phosphorylation, a metabolic profile associated with an
281 anti-inflammatory/pro-resolution phase macrophage signature (45, 46). In HBC 1 and
282 2, suppression of IL-6, IL-1, and IL-17 pathways, and activation of LXR/RXR signaling
283 pathways in SARS-CoV-2+ cases suggests involvement in resolution of inflammation,
284 as LXR/RXR pathway activation in macrophages is associated with inhibition of
285 inflammatory gene expression and promotion of lipid metabolism (47). Also consistent
286 with an anti-inflammatory role, HBC 2 showed strong suppression of the Coronavirus
287 Pathogenesis Pathway and activation of Oxytocin Signaling Pathway, the latter of which
288 is involved in attenuating oxidative and cellular inflammatory responses in macrophages
289 (48).

290 Conversely, HBC 0 and 3 demonstrated primarily activated pro-inflammatory
291 immune responses in SARS-CoV-2+ cases, with increases in LPS/IL-1 mediated
292 inhibition of RXR (HBC 3), Interferon induction (HBC 3), Neuroinflammation signaling
293 (HBC 0 and 3), T-cell signaling (HBC 0 and 3), and Production of nitric oxide and
294 reactive oxygen species (HBC 0). Metabolic processes were suppressed in both
295 clusters, including Oxytocin signaling pathway (HBC 0), Sirtuin signaling (HBC 3), and
296 MSP-RON signaling (HBC 0 and 3) (48–50). In the context of maternal SARS-CoV-2
297 infection, subcluster HBC 5 presented a mixed picture of both pro- and anti-
298 inflammatory signaling, with upregulation of interferon, EIF 2, neuroinflammation and T
299 cell related signaling pathways, balanced by upregulation of anti-inflammatory pathways
300 such as PPAR signaling and downregulation of pro-inflammatory signaling pathways
301 such as Coronavirus Pathogenesis pathway, FAK and TNF-mediated signaling
302 pathways.

303 Compared to HBC subclusters, PAMMs were less impacted overall by maternal
304 SARS-CoV-2 at a transcriptomic level, with 67 DEG identified. In the setting of maternal
305 SARS-CoV-2 infection, PAMMs showed activation of pathways involved in immune
306 responses including Production of Nitric Oxide and Reactive Oxygen Species, B-cell
307 signaling pathways, Interferon induction, and activation of the pattern recognition
308 receptor TREM-1 signaling. Similar pro-inflammatory patterns were observed for
309 monocytes, including activation of antiviral response pathways and Th1 signaling
310 pathways, and suppression of MSP-RON signaling (Figure S2C). Taken together,
311 these analyses point to transcriptional shifts in some but not all subclusters in response
312 to SARS-CoV-2, with a greater response by HBCs compared to PAMMs, driven by a

313 combination of immune activation/pro-inflammatory signature in subclusters HBC 0 and
314 HBC 3 and an anti-inflammatory tissue repair signature in clusters HBC 1 and HBC 2.

315

316 ***Maternal SARS-CoV-2 infection impacts HBC transcriptional programs associated***
317 ***with phagocytosis, neuroinflammation, and neurological disorders***

318 Tissue-resident macrophages promote resolution of inflammation through
319 phagocytosis of apoptotic cells, invading pathogens, or cellular debris (51, 52).
320 Phagocytosis is also a key function of microglia in early brain development (53–55). IPA
321 functional analysis of SARS-CoV-2-specific HBC signatures demonstrated that
322 macrophage phagocytosis (Figure 3A) and neurological disease-related pathways
323 (Figure 3B) were key functions and pathways implicated by the cluster-specific gene
324 expression signatures. Figure 3 summarizes the impact of maternal SARS-CoV-2
325 infection on placental macrophage phagocytosis (Figure 3A, 3C), illustrating the
326 potential for altered HBC gene programs to provide insight into both fetal brain
327 microglial function and the impact of maternal SARS-CoV-2 infection on
328 neurodevelopment (Figure 3B, 3D). These analyses predicted SARS-CoV-2-associated
329 suppression of phagocyte chemotaxis and cell movement pathways (e.g. reduced
330 “activation of phagocytes”, “recruitment of phagocytes”, “cell movement of phagocytes”,
331 “adhesion of phagocytes”) in HBC 1, 2 and 5, consistent with the suppression of
332 synaptosome phagocytosis (a proxy for synaptic pruning) observed in subsequent
333 experiments using in vitro Hofbauer cell induced microglial assays, detailed below. In
334 contrast to the consistent suppression of phagocytosis in HBC clusters 1, 2 and 5, HBC
335 clusters 0 and 3 and the PAMM cluster demonstrated activation of phagocytosis-related

336 pathways including “Phagocytosis” (HBC 0), “Immune response of phagocytes” (HBC
337 0), “Phagocytosis by macrophages” (HBC 3) and “Cellular infiltration by phagocytes”
338 (HBC 3). A representative phagocytosis pathway from IPA and expression of its
339 constituent genes by cluster is depicted as a heatmap in Figure 3C. Cluster-specific
340 alterations in phagocyte movement in the setting of maternal SARS-CoV-2 infection
341 were primarily driven by expression differences in *CXCL2*, *NFKB1A*, *NFKB1Z*, *IL1B*,
342 *CXCL8*, *CD36*, and *ICAM1* by cluster (Figure 3C). Concordant with patterns observed in
343 canonical pathways analyses, HBC 1 and 2 (and to a lesser extent HBC 5), which
344 showed primarily immunomodulatory signatures, also show suppressed phagocytosis
345 and phagocytic movement pathways, versus proinflammatory clusters HBC 0 and 3,
346 which demonstrate activation of phagocytosis.

347 In addition to phagocytosis, pathways relevant to neurologic disease and
348 microglial functions emerged as key dysregulated pathways in the setting of maternal
349 SARS-CoV-2 infection. We therefore assessed whether DEG of HBC subclusters map
350 to neuroinflammatory/neurodevelopmental pathways and functions in IPA, and plotted
351 pathway activation Z-scores by subcluster (Figure 3B). The transcriptional signature of
352 HBC 1 – in which Fc-gamma receptor-mediated phagocytosis (Figure 2C) and other
353 previously-described phagocytosis pathways (Figure 3A) are suppressed in SARS-CoV-
354 2+ cases – is also associated with increased neuroinflammation, including positive
355 activation Z-scores for “Inflammation of central nervous system”, “Myelitis”, and
356 “Encephalitis.” Cluster-specific expression of the genes in the “Inflammation of central
357 nervous system pathway” is depicted in Figure 3D, with upregulation of signaling in this
358 pathway driven by increased expression of *ANXA1*, *FN1*, *CCL3*, *SLC1A3*, *NLRP3*, and

359 *MERTK*, among others. Interestingly, HBC 3 – in which “Inflammation of Central
360 Nervous System” is also predicted to be activated after maternal SARS-CoV-2 infection
361 and whose transcriptional signature is consistent with activation in phagocytosis
362 pathways, also implicates increased “Apoptosis of neurons” and “Neuronal cell death”
363 (Figure 3B). In a developmental context, this pattern may represent a functional rather
364 than pathologic gene signature in response to SARS-CoV-2, as microglia (resident brain
365 macrophages) play a key role in neuronal cell turnover, regulation of neural progenitors,
366 and synaptic rewiring in early neurodevelopment, all via phagocytosis (56). Thus,
367 increased phagocytosis by tissue-resident macrophages might be an adaptive response
368 to SARS-CoV-2-associated inflammation, while reduced phagocytosis could be a
369 pathologic or maladaptive response to maternal immune activation (e.g., reduced
370 microglial phagocytosis and reduced synaptic pruning associated with maternal immune
371 activation is thought to be a key aspect of the pathogenesis of autism (57–59)). Taken
372 together, these data support the notion that HBC transcriptional signatures provide
373 insight into protective versus pathologic microglial programming in the setting of an
374 immune challenge such as SARS-CoV-2.

375 Prior work from our group in a mouse model has shown that HBCs and fetal
376 brain microglia share transcriptional profiles and responses to maternal obesity, an
377 immune-activating exposure (19). To further probe the potential connection between
378 transcriptional signatures of HBC subclusters and brain microglia in humans, we next
379 compared marker genes from HBC subclusters with gene modules from published
380 human single cell atlases of macrophages derived from adult and embryonic brain
381 (Figure 3E) (60, 61). Nearly all HBC subclusters scored highly for gene signatures

382 found in microglia, yolk sac macrophages, or CNS border associated macrophages,
383 compared with monocytes and PAMMs. HBC 2 and 1 exhibited greatest similarity to
384 yolk sac macrophages whereas HBC 3 and 4 were most like microglia isolated from
385 adult brain samples. In contrast, monocytes and PAMMs were most similar to
386 circulating monocytes, which is concordant with their shared myeloid lineage (37). This
387 analysis supports the concept that HBCs isolated from full term human placenta share
388 transcriptional signatures with yolk sac macrophages and fetal brain microglia, and thus
389 may offer insights into global reprogramming of fetal macrophage populations, including
390 those of the fetal brain, in the setting of maternal immune-activating exposures.

391

392 ***HBCs isolated from placentas of SARS-CoV-2 positive pregnancies can be***
393 ***transdifferentiated to microglia-like cells (HBC-iMGs)***

394 To gain insight into the functional consequences of SARS-CoV-2 exposure on
395 HBC populations, we used a previously-validated model in which HBCs isolated from
396 SARS-CoV-2 positive cases (N=4) and a subset of SARS-CoV-2 negative controls
397 (N=4) were cultured in media containing IL-34 and GM-CSF to obtain transdifferentiated
398 microglia-like cells (HBC-iMGs), as we have previously described (see Methods) (62–
399 64). Following culture, we assessed the expression of multiple markers associated with
400 microglial identity, including IBA1, TMEM119, PU.1, and P2RY12 (65, 66), and
401 identified expression of all markers in the majority of HBC-iMGs from both SARS-CoV-2
402 positive cases and negative controls (Figure 4A, Figure S3A-B).

403

404 ***SARS-CoV-2-exposed HBC-iMGs demonstrate increased amoeboid morphology***
405 ***and impaired phagocytic behavior compared to HBC-iMGs from uninfected***
406 ***control placentas***

407 To assess differences in cell phenotype by SARS-CoV-2 exposure, we first
408 evaluated cellular morphology of IBA1-positive HBC-iMGs by quantitative assessment
409 of two morphological characteristics: eccentricity (amoeboid vs bipolar shape) and
410 solidity (amoeboid/bipolar vs ramified shape) (Figure 4B-C). In this analysis, HBC-iMGs
411 from SARS-CoV-2 negative controls demonstrated a more ramified morphology than
412 those from positive cases, indicated by their lower solidity and high eccentricity (Figure
413 4B-C). More ramified microglial morphology is generally typical of resting-state, tissue-
414 surveilling microglia in vivo (67, 68). In contrast, a greater proportion of HBC-iMGs
415 generated from SARS-CoV-2 positive cases demonstrated higher solidity and smaller
416 cell size (Figure 4B-C, Figure S3C), consistent with a more amoeboid appearance.
417 While this morphology is classically attributed to an immune-activated state (69), it is
418 also typical of microglial patterns observed in fetal states (67, 70).

419 Transcriptional analyses of HBC clusters pointed to a cluster-specific impact of
420 maternal SARS-CoV-2 on phagocytosis pathways. HBC clusters with the greatest
421 similarity to embryonic/yolk sac microglia (e.g. HBC 1, 2) also exhibited cellular
422 programs suggestive of impaired phagocytosis. Using a previously-validated model of
423 synaptic pruning (62–64), a key physiologic function of microglia in early brain
424 development, we next tested the functional capability of HBC-iMGs to engage in
425 phagocytosis. In this assay, HBC-iMGs were co-cultured for 3 hours with pHrodo Red-
426 labeled neuronal synaptosomes derived from human induced pluripotent stem cells

427 prior to fixation and imaging. This pH-sensitive label fluoresces following intracellular
428 engulfment (see Methods). Synaptosome engulfment by IBA1-positive cells was then
429 measured by quantifying fluorescence using confocal microscopy images with
430 CellProfiler software applied for segmentation and thresholding (Figure 5A). Compared
431 to SARS-CoV-2 negative cases, HBC-iMGs from positive cases demonstrated
432 significant impairment in synaptosome phagocytosis, reflected by a reduced phagocytic
433 index (Figure 5B). Phagocytic index was reduced across all SARS-CoV-2 positive
434 samples, and was driven by reduced phagocytic uptake per cell, regardless of the
435 proportion of cells engaged in phagocytosis in any given sample. (Figure S3D-E). In
436 conjunction with the morphologic changes, and consistent with the transcriptomic
437 signatures observed in a subset of HBC, these functional phenotypes support a
438 dysregulated activation state following SARS-CoV-2 infection.

439

440 **DISCUSSION**

441 Data from observational cohorts suggests an increased neurodevelopmental risk
442 of offspring exposed *in utero* to maternal SARS-CoV-2 infection (6–8) but the underlying
443 mechanism for offspring brain vulnerability remains unknown. Studies have consistently
444 demonstrated that maternal SARS-CoV-2 infection drives alterations in immune cell
445 populations and pro-inflammatory responses at the maternal-fetal interface (71–78) that
446 have the capacity to impact the fetal brain (79). Even in the absence of direct viral
447 transmission to the fetus, profiling of umbilical cord blood immune cell populations and
448 the serum proteome demonstrates that maternal SARS-CoV-2 infection can shape fetal
449 and neonatal immunity (40, 80–82). Prior bulk and single-cell transcriptomic analyses

450 have also revealed significant reprogramming at the maternal-fetal interface following
451 SARS-CoV-2 infection during pregnancy (40, 71, 72, 77), yet granular information on
452 fetal placental cell populations has been relatively limited by their lower representation
453 in these studies.

454 Here we report single-cell RNA-seq data that provide new insights into the
455 heterogeneous functions that fetal placental macrophages, or Hofbauer cells, and
456 maternal resident placental macrophages and monocytes or PAMMs, perform at
457 baseline, and how these programs are altered in the setting of maternal SARS-CoV-2
458 infection. We found that maternal SARS-CoV-2 infection in pregnancy, even distant
459 from delivery and in the absence of placental infection, was associated with significant
460 alterations in the transcriptional programs of Hofbauer cells. These programs were more
461 significantly impacted than those of maternal placental macrophages, as indicated by
462 number of DEG. Effects of maternal SARS-CoV-2 infection were subcluster-specific,
463 with phagocytosis being a key dysregulated function, and affected Hofbauer cell
464 clusters exhibited signatures consistent with neuroinflammation and neurologic disease.
465 We directly tested this predicted dysregulation using validated in vitro models of HBC-
466 based induced microglia (HBC-iMGs) (62–64), confirming that SARS-CoV-2 infection
467 altered HBC-iMG morphology and function. SARS-CoV-2 exposed HBC-iMGs were
468 more ameboid in shape and exhibited reduced synaptosome phagocytosis, an assay
469 that serves as a proxy for synaptic pruning. Notably, reduced synaptic pruning by
470 microglia has been identified as a key mechanism in the pathogenesis of autism (57,
471 83), a neurodevelopmental disease associated with maternal immune activation and
472 viral infection in pregnancy (59, 84, 85). Considering the shared fetal origin between

473 Hofbauer cells and brain microglia (20, 21), this work indicates Hofbauer cells' potential
474 to serve as a more accessible cell type at birth that could provide information about fetal
475 brain immune programming, which in turn could alter neurodevelopmental trajectories
476 after in utero exposure to maternal SARS-CoV-2 infection.

477 Our study is unique in its in-depth, focused interrogation of fetal immune cell
478 populations of the placenta in the context of a remote maternal viral infection. Through
479 sex-chromosome-specific gene expression mapping, we were able to reliably assign
480 fetal cell identity to 8 subtypes of HBCs, engaged in a myriad of functions at baseline.
481 Similar to the work of Thomas et al. in first trimester placenta, we identified subclusters
482 with transcriptional programs associated with angiogenesis and tissue remodeling, as
483 well as clusters enriched for immune defense functions (39). Concordant with prior
484 single-cell RNA sequencing studies of the placenta in the context of SARS-CoV-2
485 infection (40, 86), we identified that even in the absence of direct placental infection or
486 active COVID-19 disease at the time of delivery, maternal exposure to SARS-CoV-2
487 remote from delivery had a profound impact on the transcriptional programs of the fetal
488 macrophage population, and to a lesser extent maternal PAMMs.

489 We defined a broad range of responses to SARS-CoV-2 across HBC
490 subclusters, including some clusters with relatively few DEG and others with significant
491 transcriptional shifts. Impacted HBC subclusters demonstrated transcriptional programs
492 evoking the changes observed in neuroinflammation, and the same subclusters
493 exhibited alterations in phagocytosis and in chemotaxis and cellular movement. To
494 investigate these results further we created induced microglial cellular models from the
495 same samples (HBC-iMG). Phenotypic and functional analyses of HBC-iMGs from

496 SARS-CoV-2 positive samples demonstrated a shift toward more amoeboid morphology
497 and significant impairments in synaptosome phagocytosis. Reduced phagocytic
498 efficiency appeared to result from reduced capacity for synaptosome uptake within the
499 cell, rather differences in the proportion of cells engaged in phagocytosis.

500 We demonstrated for the first time that HBCs can be used to create microglia-like
501 cell models, applying this approach to gain insight into fetal brain immune programming
502 in the context of maternal SARS-CoV-2 infection. As yolk-sac derived macrophages
503 that colonize the fetal brain early in development (20), microglia play a fundamental
504 role in neurogenesis by promoting neural precursor cell proliferation, axonal outgrowth,
505 and synaptic wiring throughout development (53–55). A key function of microglia in
506 normal neurodevelopment also includes selective phagocytosis of excess neuronal
507 precursors and synapses to edit and refine the architecture of neuronal communication
508 (55, 87). Evidence from animal models of maternal immune activation (MIA) suggests
509 that microglia are keenly responsive to maternal innate immune signaling, and MIA-
510 induced disruption of normal microglial function can recapitulate social deficits and other
511 behaviors correlative of those observed in neurodevelopmental disorders such as
512 autism spectrum disorder and schizophrenia (57, 58, 88, 89).

513 A primary strength of our study is inclusion of rigorously phenotyped individuals
514 without a history of prior SARS-CoV-2 infection or vaccination and of
515 contemporaneously enrolled control subjects. We thus were able to examine the
516 impact of maternal SARS-CoV-2 on an immunologically naïve cohort in the absence of
517 prior immunity to SARS-CoV-2, with a consequence being that we could not assess the
518 impact of prior vaccination. Neither the impact of COVID-19 severity nor fetal sex could

519 be assessed in this study due to the study design (primarily focused on symptomatic
520 infection and male samples as a proof of principle study) and small sample size. Sex
521 differences will be particularly important to assess in future work, given the importance
522 of fetal sex on offspring neurodevelopmental vulnerability and fetoplacental
523 programming (90, 91). Taken together, our results suggest the ability of HBC-iMGs to
524 serve as personalized cellular models of microglial programming in the setting of
525 maternal exposures, including SARS-CoV-2 and potentially other environmental
526 exposures that might impact neurodevelopment. They demonstrate potential
527 mechanisms by which these exposures may contribute to adverse neurodevelopmental
528 outcomes.

529

530 **METHODS**

531 **Study design and participant enrollment**

532 In this study, 12 pregnant individuals with full-term, singleton pregnancies delivering at
533 Massachusetts General Hospital (March 2021 - August 2021) were included.
534 Participants were classified as SARS-CoV-2 positive (N=4) if they had symptomatic
535 COVID-19 infection during pregnancy, confirmed by positive SARS-CoV-2
536 nasopharyngeal PCR test. Participants were classified as SARS-CoV-2 negative (n=8)
537 if they did not have a positive SARS-CoV-2 nasopharyngeal PCR or COVID-19
538 symptoms during pregnancy and had a negative SARS-CoV-2 nasopharyngeal PCR at
539 delivery upon universal COVID-19 screening on Labor and Delivery. Pregnant
540 individuals were eligible for inclusion if they were 18 years or older and were delivering
541 during the COVID-19 pandemic. For this study, individuals with prior COVID-19
542 vaccination were excluded. A study questionnaire and review of the electronic health
543 record was used to determine key demographic variables such as maternal age,
544 gestational age at delivery, gestational age at positive COVID-19 test, COVID-19
545 disease severity at diagnosis, any prior diagnoses of COVID-19 or history of COVID-19
546 vaccination, and infant sex and birthweight.

547

548 **Placenta collection and processing**

549 Placentas were obtained within 20 minutes after delivery and submerged in Cytowash
550 media (Dulbecco's Modified Eagle Medium (DMEM) containing 2.5% FBS, 1%
551 Penicillin-Streptomycin, 0.1% Gentamicin) and stored at 4°C until cell isolation.
552 Isolation of Hofbauer cells was performed using previously described protocols (26);

553 reagents are listed in Supplemental Table S1 and isolation workflow and study
554 procedures are depicted in Supplemental Figure S4. Briefly, placental chorionic villi
555 were separated from fetal membranes and decidua, washed in DPBS wash, and
556 mechanically homogenized. Placental tissue was then serially digested in Collagenase
557 Digestion Buffer, Trypsin Digestion Buffer, and Collagenase Digestion Buffer 2.
558 Undigested tissue was removed by passage through sterile gauze and 100uM filter. The
559 cell suspension was centrifuged at 257g for 8 min at 4°C, washed, spun again, and
560 resuspended in media. The cells were then suspended in 4mL of 20% Percoll and 5mL
561 of 35% Percoll was underlayered through a #1 glass Pasteur pipette (92). After
562 centrifugation for 30 minutes at 4°C without brake at 1000g, cells were isolated from the
563 interphase layer, washed in media, and spun at 257g for 8 minutes at 4°C. Cell pellets
564 were immunopurified by negative selection by incubation with anti-EGFR (to remove
565 syncytiotrophoblasts) and anti-CD10 (to remove fibroblasts) conjugated to magnetic
566 Dynabeads, prepared as previously described (76), for 20 minutes at 4°C. Tubes were
567 placed on a DynaMag™ magnet for 5 minutes to magnetically bind cytotrophoblasts
568 (anti-EGFR) and fibroblasts (anti-CD10) – allowing media containing unbound placental
569 macrophages to pass through into collection tubes. Cells were cryopreserved in 90%
570 FBS and 10% dimethyl sulfoxide (DMSO) at 1-10 million cells/vial and stored at -80°C
571 for downstream analyses. SARS-CoV-2 viral loads were assessed in all placental
572 tissues using qPCR as previously described, with 40 copies/mL as limit of detection (24,
573 25).

574

575 **Single-cell RNA-sequencing (scRNA-Seq) data analysis**

576

577 *Sequencing.* Cryopreserved HBCs were thawed at 37°C and diluted with RPMI 1640
578 including 10% FBS and 1% Pen/Strep. The cell suspension was centrifuged at 300g for
579 5 min at room temperature, with the brake off. The supernatant was aspirated and the
580 cell pellet was resuspended in media. Dead cells were removed using OptiPrep™
581 Density Gradient Medium (Sigma) and cell count and viability of cells were calculated
582 using LunaFX7 automated counter. Cells were immediately loaded onto 10x Genomics
583 platform with a loading target of approximately 10,000 viable cells/sample. Libraries
584 were sequenced on an Illumina NextSeq 2000 P3 flowcell machine with a sequencing
585 target of 25,000 reads per cell.

586

587 *Initial cluster identification.* Raw reads were aligned to reference genome GRCh38 and
588 quantified using Cell Ranger (version 6.0.1, 10x Genomics) and after initial cellranger
589 filtering an average of 6,295 cell/sample and 20,459 reads/cell were present. Putative
590 doublet cells were removed using predictions generated from DoubletFinder (v2.0.3) as
591 were cells containing less than 300 identified genes, which resulted in an object
592 containing 70,817 cells. All samples were integrated to remove batch effects from
593 individuals using the Seurat Single Cell Transform workflow (Seurat version 4.3.0) with
594 the top 2,000 variable features. Cells were clustered using the Louvain algorithm on the
595 shared nearest neighbor graph and visualized by UMAP using the first 30 principal
596 components. Several clustering resolutions were used to scan through the data to
597 identify a resolution (0.3) that allowed us to identify top-level cell types based on marker
598 genes. Marker genes were identified using the Wilcoxon rank sum test with the following

599 parameters: `only.pos = TRUE`, `min.pct = 0.2`, `logfc.threshold = 0.5`. Additionally,
600 expression of well-known cell-type markers was assessed to refine top-level identities:
601 hofbauer, fibroblasts, NK cells/CD8 T cells, VECs (vascular endothelial cells), EVT
602 (extravillous trophoblasts), RBCs (red blood cells), B cells, and neutrophils
603 (Supplemental Figure S1). For subsequent analyses, we created a subset of the data
604 including only cells identified as “Hofbauer,” which included macrophage and monocyte
605 populations.

606

607 *Subcluster analysis.* The data were re-integrated and processed similarly as described
608 above to identify macrophage/monocyte subclusters. Only high-quality cells were
609 retained (`mitoRatio < 0.25` and `nUMI > 1000` and `< 9681`, or 3 standard deviations
610 above the mean UMI count). The number of subclusters was optimized by iteratively
611 clustering across several cluster resolutions, and identifying the resolution that provided
612 non-redundant clusters (resolution = 0.3) as determined by marker gene identification
613 with Seurat’s Wilconcon rank-sum test (`only.pos = TRUE`, `min.pct = 0.3`, and
614 `logfc.threshold = 0.5`). Subclusters were then assigned as HBCs (0-7), PAMMs or
615 Monocytes based on marker genes. To delineate fetal from maternal origin of
616 subclusters, we evaluated sex-specific markers using only cells from placentas with a
617 male fetus (N=10). This allowed for maternal vs fetal cell differentiation, as fetal cells
618 would be expected to have increased expression of the male-specific Y-linked gene
619 *DEAD-Box Helicase 3 Y-Linked (DDX3Y)* and maternal cells would exhibit high
620 expression of the female-specific gene *X-inactive specific transcript (XIST)*. The
621 macrophage cluster with high expression of *XIST* consistent with maternal origin was

622 annotated as maternal placenta-associated macrophages and monocytes (PAMMs). To
623 further support cell cluster annotation, we also compared the overall gene expression
624 profiles of each cluster to a previously published single-cell dataset derived from human
625 first-trimester placenta and decidua (28).

626

627 *Differential gene expression by SARS-CoV-2 status.* For differential gene expression
628 analysis between cells from SARS-CoV-2 positive cases and negative controls, we
629 used the Seurat FindMarkers() within each cluster with the following parameters:
630 test.use = "MAST", min.pct = 0.3, logfc.threshold = 0.2, latent.vars = "donor". Genes with
631 Benjamini-Hochberg adjusted p-value < 0.05 were considered significant.

632

633 *Functional enrichment analyses.* Gene Ontology (GO) Biological Process enrichment
634 analysis was performed on both cluster marker genes and SARS-CoV-2 differentially
635 expressed genes in each cluster using R package clusterProfiler (v. 3.18.1) (93) and
636 underlying database AnnotationDb org.Hs.eg.db (v3.12.0). GO terms were considered
637 significant with adjusted p-value < 0.05. IPA Canonical Pathway and Diseases and
638 Functions analysis were performed with IPA (Content Version: 90348151) with
639 pathways considered significant with adjusted p-value < 0.05.

640

641 **Derivation of Hofbauer cells transdifferentiated toward microglia-like cells (HBC- 642 iMGs) by direct cytokine reprogramming**

643 HBC-iMGs were derived from HBCs using previously described methods (62–64), with
644 modifications as noted. Briefly, thawed HBCs were plated on Geltrex-coated 24-well

645 plates (1×10^6 cells in 0.5 mL per well) or 96-well plates (2×10^5 cells in 0.1mL per well)
646 depending on cell availability. After cells were incubated at 37°C for 24 h, the media was
647 completely replaced with RPMI 1640 including GlutaMAX, 1% penicillin–streptomycin,
648 100 ng/mL of human recombinant IL-34 (Peprotech), and 10 ng/mL of GM-CSF
649 (Peprotech). At day 6 of transdifferentiation, the cultures were assayed and
650 subsequently fixed with 4% PFA to perform endpoint analysis using
651 immunocytochemistry.

652

653 **HBC-iMG Immunocytochemistry**

654 HBC-iMGs were washed twice with PBS and blocked for 1 h with 5% FBS and 0.3%
655 Triton-X (Sigma Aldrich) in PBS at room temperature. Next, they were washed three
656 times with 1% FBS in PBS and incubated with primary antibodies in 5% FBS and 0.1%
657 Triton-X overnight at 4°C (Anti-IBA1, 1:500; Abcam #ab5076; Anti-TMEM119, 1:500;
658 Abcam #ab18537; Anti-CX3CR1, 1:100, Abcam #ab8021; Anti-PU.1, 1:1000, Abcam
659 #ab183327, and Anti-P2RY12, 1:100, Alomone Labs). Cells were then washed three
660 times with 1% FBS in PBS and incubated in secondary antibodies (Invitrogen Alexa
661 Fluor, 1:500) and Hoechst 33342 (1:5000) in 5% FBS and 0.1% Triton-X in PBS for
662 45 min at 4°C. Cells were washed two final times and imaged using the IN Cell Analyzer
663 6000 (Cytiva). Marker characterization was analyzed using CellProfiler (94). Cells were
664 segmented using one of the four microglia markers used and percent marker positive
665 cells calculated by dividing the number of marker positive cells by the number of
666 identified nuclei, per image. A total of 12 20x images per sample were analyzed.

667

668 **Synaptosome derivation and phagocytosis assay**

669 *Synaptosome generation from neural progenitor cell cultures.* Induced pluripotent stem
670 cells were reprogrammed from fibroblasts and used to derive expandable neural
671 progenitor cells, and large-scale differentiated neural cultures, as previously described
672 (62–64). After media removal, neural cultures were collected by scraping in 10ml per
673 T1000 flask 1× gradient buffer (ice-cold 0.32 M sucrose, 600 mg/L Tris, 1 mM
674 NaH₃CO₃, 1 mM EDTA, pH 7.4 with added HALT protease inhibitor—Thermo-Fisher
675 Scientific # 78442) and homogenized using a Dounce Tissue Grinder (Wheaton
676 #357544 15ml) with the ‘tight’ plunger. Homogenate was collected and centrifuged at
677 700g g for 10 min at 4°C to remove large debris. The gradient buffer was removed by
678 aspiration and saved on ice then the pellet was resuspended in 10 mL of 1× gradient
679 buffer and homogenization was repeated as above. The final homogenates were
680 combined and centrifuged at 15,000g for 15 min at 4°C. This second pellet was
681 resuspended in 12ml 1× gradient buffer and slowly added on top of a pre-formed
682 sucrose gradient in Ultracentrifuge Tubes (Beckman Coulter Ultra-Clear #344058)
683 containing 12ml each 1.2 M (bottom) and 0.85 M (middle) sucrose layers. The gradients
684 were centrifuged using Ultracentrifuge swinging bucket rotor #SW32TI at 26,500 RPM
685 (~80,000g) for 2 h at 4°C with the brake off. The synaptosome band (in between 0.85
686 and 1.2 M sucrose layers) was removed using a 5-mL syringe and 19Gx1 ½" needle,
687 diluted with 5-fold 1x gradient buffer then centrifuged at 20,000g for 20 min at 4°C. The
688 final pellet was resuspended in an appropriate volume of 1× gradient buffer containing
689 1 mg/mL bovine serum albumin (BSA) with HALT protease and phosphatase inhibitors
690 added, aliquoted and slowly frozen at –80°C. Protein concentration was measured by

691 BCA and enrichment of pre-synaptic (synapsin, SNAP-25) and post-synaptic (PSD-95)
692 markers was determined by western blot analysis.

693

694 *Phagocytosis Assay.* Synaptosomes were thawed and labeled with pHrodo Red SE
695 (Thermo-Fisher Scientific #P36600) at 1:2 (mg dye: mg synaptosome) and incubated at
696 room temperature for 1 hour. Labeled synaptosomes were sonicated for 1 hour before
697 adding to HBC-iMGs at 15mg total protein per well in 24-well plates, or 3mg per well in
698 96-well format. HBC-iMGs with synaptosomes were incubated at 37°C for three hours
699 and then fixed with 4% PFA for 15 minutes at room temperature. Immunocytochemistry
700 was performed to quantify phagocytosis, with images analyzed in CellProfiler (v4.2.4).
701 HBC-iMGs were segmented as described below using IBA1 staining and phagocytic
702 index was calculated by dividing the signal area of pHrodo Red by the number of
703 segmented cells, per image.

704

705 **Image analysis**

706 CellProfiler (v4.2.4) was used to identify cellular and subcellular structures in the
707 confocal images (94). The module CorrectIlluminationCalculate and
708 CorrectIlluminationApply were used in all channels to correct uneven illumination and
709 uneven background. Nuclei and cell bodies were each identified using
710 IdentifyPrimaryObjects. Specifically, pixel diameter ranges and the automatic
711 thresholding method Otsu were applied. The module RelateObjects was used to drop
712 structures incorrectly identified as nuclei by ensuring they were only accepted when
713 they have a surrounding microglia-like cell. IdentifySecondaryObjects was used to more

714 accurately outline cells around these nuclei and avoid debris. The module
715 IdentifyTertiaryObjects identified cytoplasm by subtracting the area of the nucleus from
716 the cell. IdentifySecondaryObjects was used with Otsu thresholding to identify and
717 measure synaptosomes. Background red signal was eliminated by increasing the lower
718 bounds on the automatic threshold, using reference images from Cytochalasin
719 treatment as a positive control of diminished phagocytosis. MaskObjects was used with
720 the cell and synaptosome objects to omit red signal from outside the cell. Overlays of
721 the outlines of all generated image structures were created for quality check purposes
722 using the OverlayOutlines module. Cell area, count, and signal intensity were created
723 with MeasureObjectSizeShape, MeasureObjectIntensity, ExportToSpreadSheet, and
724 ExportToDatabase. RStudio 2 (1.4) was used to organize the metadata exported from
725 CellProfiler. Phagocytic index was calculated as area of Synaptosomes divided by cell
726 count per image. As a confirmation, the integrated intensity of Synaptosome signal
727 divided by cell area was also checked to make sure both measures corresponded.
728 Images containing >80 cells were omitted due to procedure inaccuracy with dense
729 fields. Outliers were excluded by calculating a phagocytic index threshold of 3 SD above
730 the mean. Morphology data was produced using cell level metadata from CellProfiler
731 followed by a cleaning process matching the field level dataset cleaning. Cells with an
732 area or synaptosome area of greater than the mean plus 3 SD were omitted. In total, 12
733 20x images per sample were analyzed.

734

735 **Statistics**

736 Group differences were assessed using Mann-Whitney U tests. P values less than 0.05
737 were considered statistically significant. Dark lines represent median and dotted lines
738 interquartile range, unless otherwise specified. Statistical analyses were performed in
739 GraphPad Prism (version 9.3).

740

741 **Study approval**

742 This study was approved by the Mass General Brigham Institutional Review Board
743 (Protocol #2020P003538). All participants provided written informed consent prior to
744 participation.

745

746 **Data availability**

747 Sequencing data will be made available for download on GEO upon acceptance. R
748 code supporting the conclusions of this manuscript is made available here:

749 <https://github.com/rbatorsky/covid-placenta-edlow>.

750

751 **Author Contributions**

752 L.L.S. and R.A.B. contributed equally, and as co-first authors. A.G.E. conceived the
753 study and, together with R.H.P., designed the experiments. Acquisition of data: L.L.S.,
754 R.A.B., R.M.D., L.T.M., S.M.B., S.D.S., J.Z.L., S.B., J.E.H., B.A.G., R.H.P., A.G.E.
755 Analysis and interpretation of data: L.L.S., R.A.B., R.M.D., L.T.M., O.K., S.D.S., A.M.C.,
756 B.A.G., R.H.P., A.G.E. Drafting of the manuscript: L.L.S., R.A.B., R.M.D., L.T.M., A.G.E.

757 Revising the manuscript critically for important intellectual content: L.L.S., R.A.B.,
758 R.M.D., L.T.M., S.M.B., O.K., J.E.H., S.D.S., A.M.C., J.Z.L., B.A.G., R.H.P., A.G.E. All
759 authors have given final approval for submission.

760

761 **Acknowledgements:** NIH/NICHD: 1R01HD100022-01, 3R01HD100022-02S2, and
762 1U19AI167899-01 to A.G.E.; 1K12HD103096 to L.L.S.; NIH/NIMH: 1RF1MH132336-01
763 to A.G.E. and R.H.P.; NIH: 5T32HG010464 to R.M.D.; B.A.G. was supported in part by
764 the Geisel School of Medicine at Dartmouth's Center for Quantitative Biology by
765 NIH/NIGMS: P20GM130454. J.Z.L. was supported by a grant from the Massachusetts
766 Consortium for Pathogen Readiness (MassCPR).

767

768 **References:**

- 769 1. Mednick SA, et al. Adult schizophrenia following prenatal exposure to an influenza
770 epidemic. *Arch Gen Psychiatry*. 1988;45(2):189–192.
- 771 2. Barr CE, Mednick SA, Munk-Jorgensen P. Exposure to influenza epidemics during
772 gestation and adult schizophrenia. A 40-year study. *Arch Gen Psychiatry*.
773 1990;47(9):869–874.
- 774 3. Cooper SJ. Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. *Br*
775 *J Psychiatry*. 1992;161:394–396.
- 776 4. Al-Haddad BJS, et al. Long-term Risk of Neuropsychiatric Disease After Exposure to
777 Infection In Utero. *JAMA Psychiatry*. 2019;76(6):594–602.
- 778 5. Atladóttir HO, et al. Maternal infection requiring hospitalization during pregnancy and
779 autism spectrum disorders. *J Autism Dev Disord*. 2010;40(12):1423–1430.
- 780 6. Edlow AG, et al. Sex-Specific Neurodevelopmental Outcomes Among Offspring of
781 Mothers With SARS-CoV-2 Infection During Pregnancy. *JAMA Netw Open*.
782 2023;6(3):e234415.
- 783 7. Edlow AG, et al. Neurodevelopmental Outcomes at 1 Year in Infants of Mothers Who
784 Tested Positive for SARS-CoV-2 During Pregnancy. *JAMA Netw Open*.
785 2022;5(6):e2215787.
- 786 8. Santos CAD, et al. Developmental impairment in children exposed during pregnancy
787 to maternal SARS-COV2: A Brazilian cohort study. *Int J Infect Dis*. [published online
788 ahead of print: December 5, 2023]; <https://doi.org/10.1016/j.ijid.2023.12.001>

- 789 9. Pinheiro GSMA, et al. Effects of intrauterine exposure to SARS-CoV-2 on infants'
790 development: a rapid review and meta-analysis. *Eur J Pediatr.* 2023;182(5):2041–2055.
- 791 10. Kotlyar AM, et al. Vertical transmission of coronavirus disease 2019: a systematic
792 review and meta-analysis. *Am J Obstet Gynecol.* 2020;0(0).
793 <https://doi.org/10.1016/j.ajog.2020.07.049>
- 794 11. Woodworth KR, et al. Birth and Infant Outcomes Following Laboratory-Confirmed
795 SARS-CoV-2 Infection in Pregnancy - SET-NET, 16 Jurisdictions, March 29-October 14,
796 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(44):1635–1640.
- 797 12. Flaherman VJ, et al. Infant Outcomes Following Maternal Infection with SARS-CoV-
798 2: First Report from the PRIORITY Study. *Clin Infect Dis.* [published online ahead of
799 print: 2020]; <https://doi.org/10.1093/cid/ciaa1411>
- 800 13. Dumitriu D, et al. Outcomes of Neonates Born to Mothers With Severe Acute
801 Respiratory Syndrome Coronavirus 2 Infection at a Large Medical Center in New York
802 City. *JAMA Pediatr.* [published online ahead of print: October 12, 2020];
803 <https://doi.org/10.1001/jamapediatrics.2020.4298>
- 804 14. Otero AM, Antonson AM. At the crux of maternal immune activation: Viruses,
805 microglia, microbes, and IL-17A. *Immunol Rev.* 2022;311(1):205–223.
- 806 15. Simões LR, et al. Maternal immune activation induced by lipopolysaccharide
807 triggers immune response in pregnant mother and fetus, and induces behavioral
808 impairment in adult rats. *J Psychiatr Res.* 2018;100:71–83.

- 809 16. Baines KJ, et al. Maternal Immune Activation Alters Fetal Brain Development and
810 Enhances Proliferation of Neural Precursor Cells in Rats. *Front Immunol.* 2020;11:1145.
- 811 17. Careaga M, Murai T, Bauman MD. Maternal Immune Activation and Autism
812 Spectrum Disorder: From Rodents to Nonhuman and Human Primates. *Biol Psychiatry.*
813 2017;81(5):391–401.
- 814 18. Edlow AG, et al. Placental Macrophages: A Window Into Fetal Microglial Function in
815 Maternal Obesity. *Int J Dev Neurosci.* [published online ahead of print: November 20,
816 2018]; <https://doi.org/10.1016/j.ijdevneu.2018.11.004>
- 817 19. Batorsky R, et al. Hofbauer cells and fetal brain microglia share transcriptional
818 profiles and responses to maternal diet-induced obesity. *bioRxiv.*
819 2023;2023.12.16.571680.
- 820 20. Ginhoux F, et al. Fate Mapping Analysis Reveals That Adult Microglia Derive from
821 Primitive Macrophages. *Science.* 2010;330(6005):841–845.
- 822 21. Gomez Perdiguero E, et al. Tissue-resident macrophages originate from yolk-sac-
823 derived erythro-myeloid progenitors. *Nature.* 2015;518(7540):547–551.
- 824 22. Ginhoux F, Prinz M. Origin of microglia: current concepts and past controversies.
825 *Cold Spring Harb Perspect Biol.* 2015;7(8):a020537.
- 826 23. Ginhoux F, et al. Origin and differentiation of microglia. *Front Cell Neurosci.*
827 2013;7:45.

- 828 24. Fajnzylber J, et al. SARS-CoV-2 viral load is associated with increased disease
829 severity and mortality. *Nat Commun.* 2020;11(1):5493.
- 830 25. Edlow AG, et al. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load,
831 Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the
832 COVID-19 Pandemic. *JAMA Netw Open.* 2020;3(12):e2030455.
- 833 26. Tang Z, et al. Isolation of Hofbauer Cells from Human Term Placentas with High
834 Yield and Purity: ISOLATION OF PLACENTAL HOFBAUER CELLS. *Am J Reprod*
835 *Immunol.* 10/2011;66(4):336–348.
- 836 27. Megli C, Coyne CB. Gatekeepers of the fetus: Characterization of placental
837 macrophages. *J Exp Med.* 2021;218(1). <https://doi.org/10.1084/jem.20202071>
- 838 28. Suryawanshi H, et al. A single-cell survey of the human first-trimester placenta and
839 decidua. *Sci Adv.* 2018;4(10):eaau4788.
- 840 29. Pantazi P, et al. Placental macrophage responses to viral and bacterial ligands and
841 the influence of fetal sex. *iScience.* 2022;25(12):105653.
- 842 30. Heck TG, et al. Suppressed anti-inflammatory heat shock response in high-risk
843 COVID-19 patients: lessons from basic research (inclusive bats), light on conceivable
844 therapies. *Clin Sci.* 2020;134(15):1991–2017.
- 845 31. Gao X, et al. PDK4 Decrease Neuronal Apoptosis via Inhibiting ROS-ASK1/P38
846 Pathway in Early Brain Injury After Subarachnoid Hemorrhage. *Antioxid Redox Signal.*
847 2022;36(7–9):505–524.

- 848 32. Das H, et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of
849 monocytes. *Proc Natl Acad Sci U S A*. 2006;103(17):6653–6658.
- 850 33. Vijayan V, Wagener FADTG, Immenschuh S. The macrophage heme-heme
851 oxygenase-1 system and its role in inflammation. *Biochem Pharmacol*. 2018;153:159–
852 167.
- 853 34. Hou Y, et al. FABP5 controls macrophage alternative activation and allergic asthma
854 by selectively programming long-chain unsaturated fatty acid metabolism. *Cell Rep*.
855 2022;41(7):111668.
- 856 35. Dong B, et al. Macrophage-Related SPP1 as a Potential Biomarker for Early Lymph
857 Node Metastasis in Lung Adenocarcinoma. *Front Cell Dev Biol*. 2021;9:739358.
- 858 36. Li Y, et al. Nicotinamide N -methyltransferase promotes M2 macrophage
859 polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma.
860 *Hepatology*. 2023;78(5):1352–1367.
- 861 37. Thomas JR, et al. The Ontogeny and Function of Placental Macrophages. *Front*
862 *Immunol*. 2021;12:771054.
- 863 38. Sasaki Y, et al. Iba1 is an actin-cross-linking protein in macrophages/microglia.
864 *Biochem Biophys Res Commun*. 2001;286(2):292–297.
- 865 39. Thomas JR, et al. Phenotypic and functional characterization of first-trimester
866 human placental macrophages, Hofbauer cells. *J Exp Med*. 2021;218(1).
867 <https://doi.org/10.1084/jem.20200891>

- 868 40. Doratt BM, et al. Mild/asymptomatic COVID-19 in unvaccinated pregnant mothers
869 impairs neonatal immune responses. *JCI Insight*. 2023;8(19).
870 <https://doi.org/10.1172/jci.insight.172658>
- 871 41. Ripoll VM, et al. Gpnmb is induced in macrophages by IFN-gamma and
872 lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. *J*
873 *Immunol*. 2007;178(10):6557–6566.
- 874 42. Zhang H, et al. GPNMB plays an active role in the M1/M2 balance. *Tissue Cell*.
875 2022;74:101683.
- 876 43. Yaseen H, et al. Galectin-1 Facilitates Macrophage Reprogramming and Resolution
877 of Inflammation Through IFN- β . *Front Pharmacol*. 2020;11:901.
- 878 44. Tugendreich SM. Understanding biological mechanisms in transcriptomics or
879 proteomics datasets with Ingenuity Pathway Analysis (IPA) and Analysis
880 Match[https://www.dkfz.de/genomics-](https://www.dkfz.de/genomics-proteomics/fileadmin/Ingenuity/IPA_AnalysisMatch_White_paper.pdf)
881 [proteomics/fileadmin/Ingenuity/IPA_AnalysisMatch_White_paper.pdf](https://www.dkfz.de/genomics-proteomics/fileadmin/Ingenuity/IPA_AnalysisMatch_White_paper.pdf).
- 882 45. Abdalla HB, et al. Activation of PPAR- γ induces macrophage polarization and
883 reduces neutrophil migration mediated by heme oxygenase 1. *Int Immunopharmacol*.
884 2020;84:106565.
- 885 46. Viola A, et al. The Metabolic Signature of Macrophage Responses. *Front Immunol*.
886 2019;10:1462.

- 887 47. Hong C, et al. Constitutive activation of LXR in macrophages regulates metabolic
888 and inflammatory gene expression: identification of ARL7 as a direct target. *J Lipid Res.*
889 2011;52(3):531–539.
- 890 48. Szeto A, et al. Regulation of the macrophage oxytocin receptor in response to
891 inflammation. *Am J Physiol Endocrinol Metab.* 2017;312(3):E183–E189.
- 892 49. Chen YQ, Fisher JH, Wang MH. Activation of the RON receptor tyrosine kinase
893 inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate
894 macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of
895 iNOS expression. *J Immunol.* 1998;161(9):4950–4959.
- 896 50. Yoshizaki T, et al. SIRT1 inhibits inflammatory pathways in macrophages and
897 modulates insulin sensitivity. *Am J Physiol Endocrinol Metab.* 2010;298(3):E419-28.
- 898 51. A-Gonzalez N, et al. Phagocytosis imprints heterogeneity in tissue-resident
899 macrophages. *J Exp Med.* 2017;214(5):1281–1296.
- 900 52. Mosser C-A, et al. Microglia in CNS development: Shaping the brain for the future.
901 *Prog Neurobiol.* 2017;149–150:1–20.
- 902 53. Frost JL, Schafer DP. Microglia: Architects of the Developing Nervous System.
903 *Trends Cell Biol.* 2016;26(8):587–597.
- 904 54. Squarzoni P, et al. Microglia modulate wiring of the embryonic forebrain. *Cell Rep.*
905 2014;8(5):1271–1279.

- 906 55. Cunningham CL, Martínez-Cerdeño V, Noctor SC. Microglia regulate the number of
907 neural precursor cells in the developing cerebral cortex. *J Neurosci.* 2013;33(10):4216–
908 4233.
- 909 56. Hattori Y. The behavior and functions of embryonic microglia. *Anat Sci Int.*
910 2022;97(1):1–14.
- 911 57. Koyama R, Ikegaya Y. Microglia in the pathogenesis of autism spectrum disorders.
912 *Neurosci Res.* 2015;100:1–5.
- 913 58. Zhan Y, et al. Deficient neuron-microglia signaling results in impaired functional
914 brain connectivity and social behavior. *Nat Neurosci.* 2014;17(3):400–406.
- 915 59. Knuesel I, et al. Maternal immune activation and abnormal brain development
916 across CNS disorders. *Nat Rev Neurol.* 2014;10(11):643–660.
- 917 60. Bian Z, et al. Deciphering human macrophage development at single-cell resolution.
918 *Nature.* 2020;582(7813):571–576.
- 919 61. Askenase MH, et al. Longitudinal transcriptomics define the stages of myeloid
920 activation in the living human brain after intracerebral hemorrhage. *Sci Immunol.*
921 2021;6(56). <https://doi.org/10.1126/sciimmunol.abd6279>
- 922 62. Sellgren CM, et al. Patient-specific models of microglia-mediated engulfment of
923 synapses and neural progenitors. *Mol Psychiatry.* 2017;22(2):170–177.
- 924 63. Sellgren CM, et al. Increased synapse elimination by microglia in schizophrenia
925 patient-derived models of synaptic pruning. *Nat Neurosci.* 2019;22(3):374–385.

- 926 64. Sheridan SD, et al. Umbilical cord blood-derived microglia-like cells to model
927 COVID-19 exposure. *Transl Psychiatry*. 2021;11(1):179.
- 928 65. Satoh J-I, et al. TMEM119 marks a subset of microglia in the human brain.
929 *Neuropathology*. 2016;36(1):39–49.
- 930 66. Stratoulis V, et al. Microglial subtypes: diversity within the microglial community.
931 *EMBO J*. 2019;38(17):e101997.
- 932 67. Torres-Platas SG, et al. Morphometric characterization of microglial phenotypes in
933 human cerebral cortex. *J Neuroinflammation*. 2014;11:12.
- 934 68. Tremblay M-È, et al. The role of microglia in the healthy brain. *J Neurosci*.
935 2011;31(45):16064–16069.
- 936 69. Leyh J, et al. Classification of Microglial Morphological Phenotypes Using Machine
937 Learning. *Front Cell Neurosci*. 2021;15:701673.
- 938 70. Menassa DA, et al. The spatiotemporal dynamics of microglia across the human
939 lifespan. *Dev Cell*. 2022;57(17):2127-2139.e6.
- 940 71. Sureshchandra S, et al. Single-cell RNA sequencing reveals immunological rewiring
941 at the maternal-fetal interface following asymptomatic/mild SARS-CoV-2 infection. *Cell*
942 *Rep*. 2022;39(11):110938.
- 943 72. Lu-Culligan A, et al. Maternal respiratory SARS-CoV-2 infection in pregnancy is
944 associated with a robust inflammatory response at the maternal-fetal interface. *Med (N*
945 *Y)*. 2021;2(5):591-610.e10.


- 946 73. Argueta LB, et al. Inflammatory responses in the placenta upon SARS-CoV-2
947 infection late in pregnancy. *iScience*. 2022;25(5):104223.
- 948 74. Bordt EA, et al. Maternal SARS-CoV-2 infection elicits sexually dimorphic placental
949 immune responses. *Sci Transl Med*. 2021;13(617):eabi7428.
- 950 75. Gao L, et al. Single-cell analysis reveals transcriptomic and epigenomic impacts on
951 the maternal-fetal interface following SARS-CoV-2 infection. *Nat Cell Biol*.
952 2023;25(7):1047–1060.
- 953 76. Doratt BM, et al. Mild/Asymptomatic Maternal SARS-CoV-2 Infection Leads to
954 Immune Paralysis in Fetal Circulation and Immune Dysregulation in Fetal-Placental
955 Tissues. *bioRxiv*. [published online ahead of print: May 11, 2023];
956 <https://doi.org/10.1101/2023.05.10.540233>
- 957 77. Garcia-Flores V, et al. Maternal-fetal immune responses in pregnant women
958 infected with SARS-CoV-2. *Nat Commun*. 2022;13(1):320.
- 959 78. Gomez-Lopez N, et al. Pregnancy-specific responses to COVID-19 revealed by
960 high-throughput proteomics of human plasma. *Commun Med*. 2023;3(1):48.
- 961 79. Shook LL, et al. COVID-19 in pregnancy: implications for fetal brain development.
962 *Trends Mol Med*. 2022;28(4):319–330.
- 963 80. Carbonnel M, et al. Plasticity of natural killer cells in pregnant patients infected with
964 SARS-CoV-2 and their neonates during childbirth. *Front Immunol*. 2022;13:893450.

- 965 81. Foo S-S, et al. The systemic inflammatory landscape of COVID-19 in pregnancy:
966 Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2.
967 *Cell Rep Med.* 2021;2(11):100453.
- 968 82. Matute JD, et al. Single-cell immunophenotyping of the fetal immune response to
969 maternal SARS-CoV-2 infection in late gestation. *Pediatr Res.* [published online ahead
970 of print: November 8, 2021]; <https://doi.org/10.1038/s41390-021-01793-z>
- 971 83. Tang G, et al. Loss of mTOR-dependent macroautophagy causes autistic-like
972 synaptic pruning deficits. *Neuron.* 2014;83(5):1131–1143.
- 973 84. Carter M, et al. Maternal Immune Activation and Interleukin 17A in the Pathogenesis
974 of Autistic Spectrum Disorder and Why It Matters in the COVID-19 Era. *Front*
975 *Psychiatry.* 2022;13:823096.
- 976 85. Malkova NV, et al. Maternal immune activation yields offspring displaying mouse
977 versions of the three core symptoms of autism. *Brain Behav Immun.* 2012;26(4):607–
978 616.
- 979 86. Gomez-Lopez N, et al. Distinct Cellular Immune Responses to SARS-CoV-2 in
980 Pregnant Women. *J Immunol.* 2022;208(8):1857–1872.
- 981 87. Paolicelli RC, et al. Synaptic pruning by microglia is necessary for normal brain
982 development. *Science.* 2011;333(6048):1456–1458.
- 983 88. Kim HJ, et al. Deficient autophagy in microglia impairs synaptic pruning and causes
984 social behavioral defects. *Mol Psychiatry.* 2017;22(11):1576–1584.

- 985 89. Lenz KM, Nelson LH. Microglia and Beyond: Innate Immune Cells As Regulators of
986 Brain Development and Behavioral Function. *Front Immunol.* 2018;9:698.
- 987 90. Baines KJ, West RC. Sex differences in innate and adaptive immunity impact fetal,
988 placental, and maternal health. *Biol Reprod.* 2023;109(3):256–270.
- 989 91. Weinhard L, et al. Sexual dimorphism of microglia and synapses during mouse
990 postnatal development: Sexual Dimorphism in Microglia and Synapses. *Dev Neurobiol.*
991 2018;78(6):618–626.
- 992 92. Bordt EA, et al. Isolation of Microglia from Mouse or Human Tissue. *STAR Protoc.*
993 2020;1(1). <https://doi.org/10.1016/j.xpro.2020.100035>
- 994 93. Wu T, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics
995 data. *Innovation (Camb).* 2021;2(3):100141.
- 996 94. Stirling DR, et al. CellProfiler 4: improvements in speed, utility and usability. *BMC*
997 *Bioinformatics.* 2021;22(1):433.


COVID-19 infection in pregnancy	COVID-19 severity ¹	GA at SARS-CoV-2 infection (weeks)	Infant Sex	Maternal Age* (years)	GA at Delivery (weeks)	Infant birthweight (grams)
No	N/A	N/A	M	>40	39	2850
No	N/A	N/A	F	<21	40.4	3270
No	N/A	N/A	F	36-40	39	2785
No	N/A	N/A	M	31-35	37.1	3360
No	N/A	N/A	M	26-30	40.3	3670
No	N/A	N/A	M	26-30	38.9	3350
No	N/A	N/A	M	26-30	38.9	3450
No	N/A	N/A	M	36-40	39.3	3200
Yes	Severe	24	M	31-35	39	3395
Yes	Mild	28	M	26-30	40.1	3125
Yes	Mild	11	M	31-35	39.9	3370
Yes	Mild	16	M	26-30	40.3	3985

998 **Table 1. Clinical information of study participants.** GA: Gestational age. M: male. F: female. N/A: not
 999 applicable. No participants had received a COVID-19 vaccine prior to delivery. ¹COVID-19 severity was
 1000 defined by NIH criteria. *Maternal age is provided as a range to preserve participant anonymity.




1001

1002 **Figure 1. Transcriptomic profiles of fetal and maternal macrophages and monocytes isolated from term**
 1003 **placentas with and without SARS-CoV-2 infection during pregnancy. (A)** Uniform Manifold Approximation and
 1004 **Projection (UMAP) visualization of 31,719 high-quality placental macrophage and monocyte cells enriched from**
 1005 **placentas of pregnancies with (N=4) and without (N=8) SARS-CoV-2 infection shows 10 clusters. HBC: Hofbauer cell;**
 1006 **PAMM: placenta-associated maternal monocyte/macrophage. (B)** Cluster-specific expression of *DDX3Y*, expressed
 1007 **only in fetal cells, and *XIST*, expressed only in maternal cells, in placentas from individuals carrying a male fetus (N=10).**
 1008 **(C)** Correlation of cluster-average gene expression with annotated cell types identified by Suryawanshi et al., *Sci Adv*,
 1009 **2018. Each heatmap shows Spearman correlation coefficients. Highest correlation coefficient per cluster is indicated**
 1010 **by black dots. HBC clusters were most highly correlated with Suryawanshi HBC clusters, PAMM cluster most correlated**
 1011 **with decidual macrophages. (D)** Heatmap displaying expression (\log_2 fold change) of the top 5 marker genes per
 1012 **cluster. (E)** Gene Ontology (GO) Biological Process enrichment analysis for cluster marker genes. GO terms displayed
 1013 **were curated from the top significant GO terms in each cluster, selecting the processes most relevant to macrophage**
 1014 **function, and reducing redundancy. Gene Count gives the number of genes in the query set that are annotated by the**
 1015 **relevant GO category. GO terms with an adjusted p-value < 0.05 were considered significantly enriched.**




1016

1017 **Figure 2. Impact of maternal SARS-CoV-2 infection on Hofbauer cell subclusters.** DEG: differentially expressed
 1018 genes. **(A)** Barplot demonstrating proportion of cells per cluster from SARS-CoV-2 positive cases (red) and negative
 1019 controls (gray), top panel. Number of DEG upregulated (dark blue) and downregulated (light blue) by SARS-CoV-2
 1020 exposure per cluster, bottom panel. **(B)** Gene Ontology (GO) Biological Process enrichment analysis for DEG. Gene
 1021 Count gives the number of genes in the query set that are annotated by the relevant GO category. GO terms with an
 1022 adjusted p-value < 0.05 were considered significantly enriched. **(C)** Ingenuity Pathway Analysis (IPA) of DEG for HBC
 1023 clusters 0 (left) and 1 (right). Canonical pathways with absolute Z-score ≥ 1 and adjusted p-value < 0.05 are shown.
 1024 IPA analysis for remaining HBC clusters depicted in Supplement.




1025
 1026 **Figure 3. Impact of maternal SARS-CoV-2 on HBC gene programs associated with phagocytosis and neurologic**
 1027 **disease. (A-B)** Ingenuity Pathway Analysis (IPA) phagocytosis diseases and functions pathways **(A)**, and neurologic
 1028 diseases and functions **(B)**, enriched for ≥ 3 DEGs, with absolute Z-score ≥ 1 and adjusted P-value < 0.05 . Activation Z-
 1029 score represented by color and number of DEGs by circle size, with red color indicating pathway activation and blue
 1030 color indicating suppression. **(C-D)** Heatmap of gene expression in “Cellular Infiltration by Phagocytes” IPA Pathway
 1031 **(C)** and “Inflammation of Central Nervous System” **(D)** by cluster. Color represents gene expression level (\log_2 fold
 1032 change), *adjusted P-value < 0.05 . **(E)** Module score by subcluster in comparison to cluster-specific gene expression
 1033 of single-cell datasets from human brain: Microglia and Border Associated Macrophages (Askenase et al., *Sci Immunol*,
 1034 2021) and Yolk Sac Macrophages and Monocytes (Bian et al., *Nature*, 2020). Color indicates module score.



1035

1036 **Figure 4. Phenotypic characterization of HBC-iMGs by direct cytokine reprogramming.** HBC-iMGs: Hofbauer
 1037 cells transdifferentiated toward microglia-like cells. (A) Images of HBC-iMGs from SARS-CoV-2 positive cases (n=4)
 1038 and negative controls (n=4), immunostained for microglial markers: IBA1, PU.1, P2RY12, TMEM119. Scale bar = 100
 1039 μm . (B) Morphology-smoothed density plots (solidity vs. eccentricity) for SARS-CoV-2 negative and positive samples
 1040 as indicated. Cells from negative controls exhibit a more ramified morphology than those from positive cases,
 1041 suggestive of a less activated phenotype. Red color shows high density and blue is low density. Representative
 1042 confocal microscopy images of amoeboid, bipolar, and ramified HBC-iMGs. Scale bar = 50 μm . (C) Violin plots
 1043 represent distribution of cell solidity (left) and eccentricity (right) measurements from SARS-CoV-2 negative controls
 1044 (blue, n=5223 cells) and positive cases (orange, n=237 cells). Solid lines represent median values and dashed lines
 1045 interquartile range. Group differences assessed by Mann-Whitney U Test. ****P<0.0001. ns = not significant.



1046

1047 **Figure 5. Impact of maternal SARS-CoV-2 on HBC-iMG synaptosome engulfment.** HBC-iMGs: Hofbauer cells
1048 transdifferentiated toward microglia-like cells. (A) Representative image showing colocalization of pHrodo-red labeled
1049 synaptosomes (SYN) and IBA1 positive HBC-iMGs. Hoechst = nuclear stain. Scale bar = 100 µm. (B) Violin plots of
1050 phagocytic index of image fields from SARS-CoV-2 negative controls (blue, n=187 fields) and positive cases (orange,
1051 n=32 fields). Phagocytic index is calculated as synaptosome area in pixels divided by cell count per image field. Solid
1052 lines represent median values and dashed lines interquartile range. Group differences assessed by Mann-Whitney U
1053 Test. ****P<0.0001.